



KAMUYU AYDINLATMA PLATFORMU

EİS ECZACIBAŞI İLAÇ SİNAİ VE FİNANSAL YATIRIMLAR SANAYİ VE TİCARET A.Ş. Material Event Disclosure (General)

Summary

Launch of accelerated bookbuilding transaction to qualified investors



**MERKEZİ KAYIT
İSTANBUL**
Türkiye Sermaye Piyasası - Merkezi
Saklama ve Veri Depolama Kuruluşu

Material Event Disclosure General

Related Companies [ECZYT]

Related Funds []

Material Event Disclosure General	
Update Notification Flag	Hayır (No)
Correction Notification Flag	Hayır (No)
Date Of The Previous Notification About The Same Subject	-
Postponed Notification Flag	Hayır (No)
Announcement Content	
Explanations	

You may find below the disclosure communicated by our shareholder Eczacıbaşı Holding A.Ş.

Eczacıbaşı Holding A.Ş. ("Eczacıbaşı Holding") announces the launch of the placement of TRY 20,200,000 nominal value shares in EİS Eczacıbaşı İlaç, Sınai ve Finansal Yatırımlar Sanayi ve Ticaret A.Ş. ("Eczacıbaşı İlaç") representing approximately 2.95% of its issued share capital (the "Transaction").

The sale will be made by way of a placement to qualified investors in and outside of Türkiye. The price per share in the Transaction will be determined through an accelerated bookbuilding process which will commence immediately. Eczacıbaşı Holding reserves the right to change the terms and timing of the Transaction at any time. The final terms of sale like nominal value of shares sold and price will be announced. Eczacıbaşı İlaç will not receive any proceeds from the Transaction. Eczacıbaşı Holding will use the proceeds from the Transaction in line with its strategic objectives.

HSBC Bank plc ("HSBC") will act as the Sole Global Coordinator and Bookrunner (the "Sole Global Coordinator") to Eczacıbaşı Holding in relation to the Transaction.

It is expected that, in order to facilitate the settlement of the Transaction as a wholesale transaction (toptan alım satım işlemi), HSBC Yatırım Menkul Değerler A.Ş. will apply to Borsa İstanbul A.Ş. (the "BİST") on 14 April 2026. Subject to the timing of the approval of BİST, the trade relating to the Transaction is expected to be effected on 15 April 2026 and is expected to settle as wholesale transaction (toptan alım satım işlemi) on 17 April 2026. As of today, all the shares subject to the Transaction are not in tradable form, and the conversion process to render such shares tradable on BİST is expected to be completed as of the date of the wholesale transaction. Following the Transaction free float ratio of Eczacıbaşı İlaç shares is expected to increase.

Eczacıbaşı Holding currently holds directly approximately 50.62% of the issued share capital in Eczacıbaşı İlaç and following the successful completion of the Transaction, Eczacıbaşı Holding's direct shareholding ratio in Eczacıbaşı İlaç is expected to be approximately 47.67%. Eczacıbaşı Holding's subsidiary Eczacıbaşı Yatırım Holding Ortaklığı A.Ş. ("Eczacıbaşı Yatırım Holding"), which holds 30.62% of the issued share capital in Eczacıbaşı İlaç, will not be selling any shares of Eczacıbaşı İlaç in the Transaction. Eczacıbaşı Holding will remain the major shareholder of Eczacıbaşı İlaç.

Eczacıbaşı Holding has undertaken to the Sole Global Coordinator not to sell any of its shares in Eczacıbaşı İlaç for 90 days following the settlement date of the Transaction, including any shares held by controlled entities, subject to customary exceptions or any transactions carried out with the consent of the Sole Global Coordinator.

* Eczacıbaşı Holding holds approximately 81.57% of Eczacıbaşı Yatırım Holding shares.

**Eczacıbaşı İlaç holds 37.28% of Eczacıbaşı Holding shares, and Eczacıbaşı Yatırım Holding holds 11.54% of Eczacıbaşı Holding shares.

Legal Disclaimer

HSBC is authorised by the Prudential Regulation Authority ("PRA") and regulated in the United Kingdom by the Financial Conduct Authority ("FCA") and the PRA. HSBC is acting for Eczacıbaşı Holding only in connection with the Transaction and no one else, and will not be responsible to anyone other than Eczacıbaşı Holding for providing the protections offered to clients nor for providing advice in relation to the shares subject to the Transaction or the Transaction, the contents of this announcement or any transaction, arrangement or other matter referred to in this announcement.

In connection with the Transaction, HSBC and any of its affiliates may take up a portion of the securities as a principal position and in that capacity may retain, purchase, sell, offer to sell or otherwise deal for their own accounts in such securities and other securities of Eczacıbaşı İlaç or related investments in connection with the Transaction or otherwise. Accordingly, references in this announcement to the securities being offered, sold, acquired, placed or otherwise dealt in should be read as including any offer, sale, acquisition, placing or dealing by HSBC and any of its affiliates in such capacity. In addition, HSBC and any of its affiliates may enter into financing arrangements (including swaps, warrants or contracts for difference) with investors in connection with which HSBC and any affiliates may from time to time acquire, hold or dispose of securities. None of HSBC nor any of its affiliates intends to disclose the extent of any such investment or transactions otherwise than in accordance with any legal or regulatory obligation to do so.

Neither HSBC nor any of its affiliates, directors or employees owes or accepts any duty, liability or responsibility whatsoever (whether direct or indirect, consequential, whether in contract, in tort, in delict, under statute or otherwise) to any person who is not a client of HSBC in connection with this announcement, any statement contained herein, the Transaction or otherwise. An investor must seek its own advice from its accountant, broker, custodian, legal counsel or other professional adviser as it deems necessary.

There is also a Turkish version of this disclosure and in case of any discrepancy between two versions; the Turkish version will prevail.

We proclaim that our above disclosure is in conformity with the principles set down in “Material Events Communiqué” of Capital Markets Board, and it fully reflects all information coming to our knowledge on the subject matter thereof, and it is in conformity with our books, records and documents, and all reasonable efforts have been shown by our Company in order to obtain all information fully and accurately about the subject matter thereof, and we’re personally liable for the disclosures.